BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31808253)

  • 1. Drug-eluting versus bare-metal stents for saphenous vein graft lesions.
    Conte SM; Florisson DS; De Bono JA; Vale PR
    Intern Med J; 2019 Dec; 49(12):1534-1537. PubMed ID: 31808253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.
    Mehilli J; Pache J; Abdel-Wahab M; Schulz S; Byrne RA; Tiroch K; Hausleiter J; Seyfarth M; Ott I; Ibrahim T; Fusaro M; Laugwitz KL; Massberg S; Neumann FJ; Richardt G; Schömig A; Kastrati A;
    Lancet; 2011 Sep; 378(9796):1071-8. PubMed ID: 21872918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Intervention.
    Patel NJ; Bavishi C; Atti V; Tripathi A; Nalluri N; Cohen MG; Kini AS; Sharma SK; Dangas G; Bhatt DL
    Circ Cardiovasc Interv; 2018 Nov; 11(11):e007045. PubMed ID: 30571204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug eluting versus bare metal stents for percutaneous coronary intervention of saphenous vein graft lesions: An updated meta-analysis of randomized controlled trials.
    Ha FJ; Nogic J; Montone RA; Cameron JD; Nerlekar N; Brown AJ
    Cardiovasc Revasc Med; 2018; 19(7 Pt B):837-844. PubMed ID: 29685385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions.
    Rozenman Y
    JACC Cardiovasc Interv; 2011 May; 4(5):590-1; author reply 591-3. PubMed ID: 21596337
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of long-term outcomes of drug-eluting stents and bare metal stents for saphenous vein graft stenosis.
    Chakravarty T; Morrissey RP; Wertman B; Naghi J; Chou S; Goykhman P; Doctor N; Mirocha J; Forrester JS; Makkar R
    Catheter Cardiovasc Interv; 2012 May; 79(6):903-9. PubMed ID: 21805570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients.
    Hakeem A; Helmy T; Munsif S; Bhatti S; Mazraeshahi R; Cilingiroglu M; Effat M; Leesar M; Arif I
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):343-55. PubMed ID: 21328679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating saphenous vein graft lesions: Drug-eluting stents are not the answer!
    Hall AB; Brilakis ES
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):E193-E194. PubMed ID: 30770658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting versus bare-metal stents in saphenous vein graft lesions.
    Brilakis ES; Banerjee S; Shunk KA; Bhatt DL
    Lancet; 2012 Feb; 379(9816):615; author reply 615-6. PubMed ID: 22340298
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: from Western Denmark Heart Registry.
    Hougaard M; Thayssen P; Kaltoft A; Tilsted HH; Maeng M; Lassen JF; Thuesen L; Okkels Jensen L
    Catheter Cardiovasc Interv; 2014 Jun; 83(7):1035-42. PubMed ID: 24311384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-eluting vs. bare metal stent implantation in saphenous vein graft lesions: Very long-term follow-up of the SOS (Stenting of Saphenous vein grafts) trial.
    Sosa A; Chao H; Guerra A; Han H; Christopoulos G; Christakopoulos GE; Tarar MN; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Banerjee S; Brilakis ES
    Int J Cardiol; 2015; 186():261-3. PubMed ID: 25828130
    [No Abstract]   [Full Text] [Related]  

  • 13. A comprehensive meta-analysis of randomized controlled trials comparing drug-eluting stents with bare-metal stents in saphenous vein graft interventions.
    Shah R; Jovin IS; Latham SB; Hesterberg K; Heckle MR; Rashid A; Vetrovec GW
    Catheter Cardiovasc Interv; 2018 Dec; 92(7):1229-1236. PubMed ID: 30051628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
    Wöhrle J; Nusser T; Kestler HA; Kochs M; Hombach V
    Clin Res Cardiol; 2007 Feb; 96(2):70-6. PubMed ID: 17146605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions.
    Colleran R; Kufner S; Mehilli J; Rosenbeiger C; Schüpke S; Hoppmann P; Joner M; Mankerious N; Fusaro M; Cassese S; Abdel-Wahab M; Neumann FJ; Richardt G; Ibrahim T; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    J Am Coll Cardiol; 2018 May; 71(18):1973-1982. PubMed ID: 29724350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The final answer? For the treatment of saphenous vein graft disease, drug-eluting stents vs. bare-metal stents.
    Michishita I
    Circ J; 2011; 75(2):261-2. PubMed ID: 21228495
    [No Abstract]   [Full Text] [Related]  

  • 19. Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions.
    Ybarra LF; Ribeiro HB; Pozetti AH; Campos CA; Esper RB; Lemos PA; Lopes AC; Kalil-Filho R; Ellis SG; Ribeiro EE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E856-63. PubMed ID: 23239630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stents and failing vein grafts: are we any wiser after ISAR?
    Taggart DP; Banning AP
    Lancet; 2011 Sep; 378(9796):1054-5. PubMed ID: 21872921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.